

GOG 278

PROTOCOL GOG-0278

EVALUATION OF PHYSICAL FUNCTION AND QUALITY OF LIFE (QOL) BEFORE
AND AFTER NON-RADICAL SURGICAL THERAPY (EXTRA FASCIAL
HYSTERECTOMY OR CONE BIOPSY WITH PELVIC LYMPHADENECTOMY) FOR
STAGE IA1 (LVSI+) and IA2-IB1 (≤ 2 CM) CERVICAL CANCER

NCI Version Date 09/20/2012

POINTS:

PER CAPITA - 20

MEMBERSHIP - 6


PI = AL COVENS

N = 220

Enrollment to date = 162

Primary Endpoint = QOL

AIM2CERV / GOG 3009



Baseline tumor imaging must be performed within 28 days prior to the first study treatment infusion

Randomization 1:2 Reference and Treatment Groups

Primary Objective is Progression Free Survival

PI = THOMAS HERZOG MD

N = 455

Enrollment to date = 61 (18 GOG)

Primary Endpoint = RFS

NRG Oncology (GOG/RTOG)

Current GCIIG Studies in the NRG


1. **NRG 278**
2. NRG 263 (KGOG 0801)
3. NRG 0724 (RTOG)
4. NRG 0274 (ANZGOG OUTBACK)
5. **AIM2CERV/GOG 3009**
6. **NRG GY006**
7. TIME-C (RTOG)
8. NRG 270 (GROINSS-V II)
9. **NRG 279**
10. **GOG 3016**




GOG-3016 (R2810-ONC-1676)

- Recurrent, persistent, and/or metastatic cervical cancer
- Progressed within 6 months of the last dose of platinum

R
A
N
D
O
M
I
Z
E



REGN2810 350 mg Q3W,
for up to 96 weeks



Physicians choice chemotherapy

Pemetrexed 500 mg/m² Q3W

Topotecan 1 mg/m² daily for 5 days, Q21 days

Irinotecan 100 mg/m² days 1, 8, 15, & 22,
followed by 2 weeks rest (6-week cycle)

Vinorelbine 30 mg/m² days 1 & 8, Q21 days

Gemcitabine 1000 mg/m² on days 1 & 8, Q21 days

PI = Krishnansu S. Tewari, MD
N = 436
Primary Endpoint = OS
Enrollment = 53 (15 GOG)

REGN2810, a fully human monoclonal antibody against programmed death-1 (PD-1)

GOG 279

PROTOCOL GOG-0279

A PHASE II TRIAL EVALUATING CISPLATIN (NSC #119875) AND GEMCITABINE (NSC # 613327) CONCURRENT WITH INTENSITY-MODULATED RADIATION THERAPY (IMRT) IN THE TREATMENT OF LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE VULVA

NCI Version Date: 11/02/2012

Includes Revision #1

POINTS:

PER CAPITA - 20

MEMBERSHIP - 3

Study Chair: NS Horowitz MD
Target 52 evaluable patients
Enrollment to date = 36